Morinaga Soichiro, Nakamura Yoshiyasu, Ishiwa Naoki, Yoshikawa Takaki, Noguchi Yoshikazu, Yamamoto Yuji, Rino Yasushi, Imada Toshio, Takanashi Yoshinori, Akaike Makoto, Sugimasa Yukio, Takemiya Shoji
Department of Surgery, Yokohama City Kowan Hospital, Nakaku, Yokohama 231-0801, Japan.
Oncol Rep. 2004 Dec;12(6):1189-94.
The clinical impact of survivin on human cancer pathogenesis and prognosis has been investigated. To clarify the clinical effect of survivin on tumor behavior and prognosis of patients with hepatocellular carcinoma (HCC), the expression of survivin mRNA in 40 samples of HCC tissue and matched-adjacent liver tissue, as well as 7 healthy hepatic tissue samples were measured by a real-time reverse transcription polymerase chain reaction. The expressed level of survivin mRNA (log copies/microg total RNA) in healthy liver tissue was 1.95+/-0.44, in morbid liver tissue adjacent to the tumors was 4.79+/-0.96, and in HCC tissue was 5.87+/-0.73 (values are mean +/- SD and P<0.001). The amount of survivin mRNA in HCC tissues correlated negatively with the apoptotic indices (r=-0.573 and P<0.001) and correlated positively with the proliferation indices (r=0.433 and P=0.005). Expression of survivin was significantly related with histologic grade (P=0.011) and pathological tumor stage (P=0.017). Patients with HCC tumors that had a large amount of survivin mRNA (> or = mean) had lower survival rate (P=0.030), but multivariate analysis showed only Ki-67 labeling index, histologic grade, and pathologic T stage to be the independent prognosticators. These findings indicate that survivin is associated with reduced tumor cell apoptosis, increased tumor cell proliferation, and histologically aggressive tumor features, and may play an important role in tumor progression of HCC. However, further examination is needed to clarify its predictive significance for HCC patients.
已对生存素在人类癌症发病机制和预后方面的临床影响进行了研究。为阐明生存素对肝细胞癌（HCC）患者肿瘤行为和预后的临床作用，采用实时逆转录聚合酶链反应检测了40例HCC组织样本、配对的癌旁肝组织样本以及7例健康肝组织样本中生存素mRNA的表达情况。健康肝组织中生存素mRNA的表达水平（log拷贝数/μg总RNA）为1.95±0.44，肿瘤旁病肝组织中为4.79±0.96，HCC组织中为5.87±0.73（数值为平均值±标准差，P<0.001）。HCC组织中生存素mRNA的量与凋亡指数呈负相关（r=-0.573，P<0.001），与增殖指数呈正相关（r=0.433，P=0.005）。生存素的表达与组织学分级（P=0.011）和病理肿瘤分期（P=0.017）显著相关。生存素mRNA含量高（≥平均值）的HCC肿瘤患者生存率较低（P=0.030），但多因素分析显示只有Ki-67标记指数、组织学分级和病理T分期是独立的预后因素。这些发现表明，生存素与肿瘤细胞凋亡减少、肿瘤细胞增殖增加以及组织学上侵袭性肿瘤特征相关，可能在HCC的肿瘤进展中起重要作用。然而，需要进一步研究以阐明其对HCC患者的预测意义。
